Nuvalent Files 8-K: Other Events & Financials
Ticker: NUVL · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1861560
Sentiment: neutral
Topics: 8-K, reporting, financials
TL;DR
Nuvalent filed an 8-K on 9/16 for events on 9/14. Standard reporting.
AI Summary
Nuvalent, Inc. filed an 8-K on September 16, 2024, reporting on other events and financial statements. The filing date for the report is September 14, 2024. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This filing provides an update on Nuvalent's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for reporting events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-40671 — SEC File Number (Identifies the company's filing history with the SEC.)
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Nuvalent, Inc. (company) — Registrant
- September 14, 2024 (date) — Earliest event reported
- September 16, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Cambridge, Massachusetts (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond listing the item category.
What is the significance of the 'Conformed Period of Report' date?
The 'Conformed Period of Report' date of September 14, 2024, indicates the period to which the reported events or information primarily pertains.
What is Nuvalent, Inc.'s Standard Industrial Classification (SIC) code?
Nuvalent, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What is the company's principal executive office address?
The principal executive offices are located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142.
What is the registrant's telephone number?
The registrant's telephone number is (857) 357-7000.
Filing Stats: 1,155 words · 5 min read · ~4 pages · Grade level 14.9 · Accepted 2024-09-16 06:05:30
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
Filing Documents
- d862522d8k.htm (8-K) — 30KB
- d862522dex991.htm (EX-99.1) — 66KB
- g862522g0913031014890.jpg (GRAPHIC) — 3KB
- 0001193125-24-219153.txt ( ) — 239KB
- nuvl-20240914.xsd (EX-101.SCH) — 3KB
- nuvl-20240914_lab.xml (EX-101.LAB) — 18KB
- nuvl-20240914_pre.xml (EX-101.PRE) — 11KB
- d862522d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Nuvalent, Inc. on September 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K, including Exhibit 99.1 hereto, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the Company's strategy, business plans, and focus; the clinical development programs for zidesamtinib and NVL-655; the expected timing of reporting data readouts from the Company's clinical trials of zidesamtinib and NVL-655; the design and timing of the ALKAZAR trial, including alignment with the U.S. Food and Drug Administration (the "FDA") regarding the design of the trial; the potential clinical effects of zidesamtinib and NVL-655; the potential of the Company's pipeline programs, including zidesamtinib and NVL-655; the implications of data readouts and presentations; the Company's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this Current Re